Document:

<PAGE>

                                                                   EXHIBIT 10.55

                        FACILITIES CONTRIBUTION AGREEMENT

        This Facilities Contribution Agreement (the "Agreement") is made with
retroactive effect to November 1st, 2001 by and between Connetics Corporation, a
Delaware corporation, with its principal place of business at 3290 West Bayshore
Road, Palo Alto, California 94303 ("Connetics") and DPT Laboratories, Ltd., a
Texas Limited Partnership with a place of business at 307 East Josephine Street,
San Antonio, Texas 78215 ("DPT"). Connetics and DPT are sometimes referred to in
this Agreement individually as a "Party" and collectively as the "Parties."

                                   BACKGROUND

A.      DPT leases certain Premises currently partially improved with a facility
        being constructed thereon, legally described on EXHIBIT A to this
        Agreement (the "PREMISES"). DPT also owns certain contract rights,
        plans, drawings, specifications and reports used in connection with the
        pharmaceutical qualification and validation, and improvement of the
        Premises and construction of the Project (defined below).

B.      Pursuant to this Agreement, DPT has agreed to permit Connetics to
        construct certain improvements on the Premises and install certain
        equipment on the Premises, as more specifically described herein.

C.      Pursuant to this Agreement, Connetics shall contribute the costs for the
        construction of the improvements and purchase of the equipment, as more
        specifically described herein.

D.      Pursuant to this Agreement and the plans, specifications, and other
        documents required hereby, DPT has agreed to assist Connetics as an
        advisor in connection with the Project on the Premises.

The Parties agree as follows:

                                    ARTICLE 1
                                   DEFINITIONS

As used in this Agreement, the following capitalized terms have the following
meanings:

"APPROVED PLANS" means the Premises Improvement Plans (Plans and specifications
prepared by the Architect and DPT), as approved by DPT and Connetics.

"ARCHITECT" means Middleman + de la Garza + Neugebauer Architects or such other
person or firm as Connetics and DPT may mutually agree.

"ASSETS" shall have the meaning set forth in SECTION 5.1.

                                     Page 1
<PAGE>

"cGMP" means the current Good Manufacturing Practices of the FDA, as set forth
in Title 21 of the U.S. Code of Federal Regulations.

"CHANGE ORDER" shall have the meaning set forth in SECTION 3.3 of this
Agreement.

"CONNETICS CONTRIBUTION" shall have the meaning set forth in SECTION 2.1 of this
Agreement.

"CONNETICS DELAY" means any of the following types of delay in the completion of
construction of the Project:

        (1) Any delay resulting from Connetics' failure to furnish, in a timely
        manner, information recommended by DPT or by the Architect or General
        Contractor for the Project in connection with the design or construction
        of the Project, or from Connetics' failure to approve in a timely manner
        any matters requiring approval by Connetics;

        (2) Any delay resulting from Change Orders requested by Connetics,
        including any delay resulting from the need to revise any drawings or
        obtain further governmental approvals as a result of any Change Order;
        or

        (3) Any material delay of any other kind or nature caused by Connetics
        (or Connetics' contractors, agents or employees).

"DPT DELAY" means any of the following types of delay in the completion of
construction of the Improvements:

        (1) Any delay resulting from DPT's failure to furnish, in a timely
        manner, information requested by the Architect or General Contractor for
        the Work in connection with the design or construction of the
        Improvements; or

        (2) Any material delay of any other kind or nature caused by DPT (or
        DPT's contractors, agents or employees).

"EQUIPMENT" means the production scale equipment and laboratory scale equipment
purchased by Connetics and utilized in the Project.

"GENERAL CONTRACTOR" means Capstone Corporation, or any other general contractor
recommended by DPT and selected by Connetics.

"IMPROVEMENTS" means the Project and other improvements shown on the Approved
Plans from time to time and to be constructed on the Premises pursuant to this
Agreement.

"OPERATING EXPENSES" shall have the meaning set forth in SECTION 5.4.

"PROJECT" means the design, construction and management of a cGMP qualified
aerosol filling facility on the Premises in accordance with the Approved Plans,
including (a) any necessary site improvements; and (b) other improvements
necessitated by the construction of the facility.

                                     Page 2
<PAGE>

"PUNCH LIST WORK" means minor corrections of construction or decoration details,
and minor mechanical adjustments, that are required in order to cause any
applicable portion of the Improvements as constructed to conform to the Approved
Plans in all material respects and that do not materially interfere with the use
or occupancy of the Premises.

"SUBSTANTIAL COMPLETION OF THE PROJECT" means the completion of the Project
(except for Punch List Work), in good and workmanlike condition, in compliance
with all applicable requirements, and in conformance with the Approved Plans.

"UNAVOIDABLE DELAYS" means delays due to acts of God, acts of public agencies,
labor disputes, strikes, fires, freight embargoes, rainy or stormy weather,
inability to obtain supplies, materials, fuels or permits, delays of contractors
or subcontractors, or other causes or contingencies beyond the reasonable
control of DPT or Connetics, as applicable.

                                    ARTICLE 2
                                  CONTRIBUTION

        SECTION 2.1. CONNETICS CONTRIBUTION. Connetics agrees to pay the costs
associated with construction of the Project and the purchase of production scale
equipment (currently estimated at Two Million Six Hundred Twenty-Five Thousand
Five Hundred and Twenty-Five Dollars ($2,625,525) and to contribute an
additional One Hundred Twenty One Thousand Dollars ($121,000) for the purchase
of laboratory scale equipment for use in the Project, subject to all of the
terms, covenants and conditions set forth in this Agreement. Connetics' cash
contribution and the Equipment are collectively referred to as "Connetics'
Contribution." In the event additional capital requirements are required, DPT's
obligations herein shall be conditioned upon Connetics agreement to fund the
additional capital.

        SECTION 2.2. PREMISES. The Premises are located at 5303 Distribution
Drive and the laboratory scale equipment is located at 307 E. Josephine St., San
Antonio, Texas 78218.

        SECTION 2.3. ACCOUNTING. No less often than monthly, DPT shall provide
Connetics with a written accounting of all amounts spent on the Project to that
date, in a level of detail reasonably satisfactory to Connetics.

                                    ARTICLE 3
                              PROJECT CONSTRUCTION

DPT and Connetics shall comply with the procedures set forth in this ARTICLE 3
in preparing, delivering and approving matters relating to the Project.

        SECTION 3.1. APPROVED PLANS. DPT and Connetics shall cooperate with
Architect in the development of the Premises Improvement Plans and
specifications for the Project (once such plans and specifications are approved
by DPT and Connetics, the "Approved Plans").

                                     Page 3
<PAGE>

        SECTION 3.2. CONSTRUCTION OF PROJECT. The Project will be constructed on
the Premises. Except as otherwise expressly provided in this Agreement or by
mutual written agreement of DPT and Connetics, the cost of construction of the
Project shall be borne by Connetics at its sole cost and expense, including any
costs or cost increases incurred as a result of Unavoidable Delays, governmental
requirements or unanticipated conditions. Upon receipt of necessary permits and
approvals, DPT shall (except as otherwise provided in this Agreement),
diligently manage and oversee the construction and completion of the Project
substantially in accordance with the Approved Work Plans, subject to Unavoidable
Delays and Connetics Delays (if any). It is understood that DPT shall provide
construction and engineering supervision of the Project, but will not act as the
General Contractor for the Project. Such construction shall conform, in all
material respects, to all applicable governmental codes, laws and regulations in
force at the time such work is completed. DPT shall provide formal progress
updates on the Project to Connetics as appropriate during the construction,
validation, and commissioning process.

        SECTION 3.3. CHANGES.

               (a) By DPT. If DPT recommends at any time that changes in the
        Approved Plans relating to any item of the Project are required as a
        result of applicable law or governmental requirements, or at the
        insistence of any other third party whose approval may be required with
        respect to the Project, or as a result of unanticipated conditions
        encountered in the course of construction, then DPT shall promptly
        advise Connetics of such circumstances in the form of a detailed written
        request specifying such changes, alterations or additions. Upon receipt
        of any such request, Connetics shall notify DPT as soon as is reasonably
        possible whether the recommendations are agreeable (which approval shall
        not be unreasonably withheld, delayed or conditioned). Upon Connetics'
        approval, Connetics shall enter into a Change Order with the General
        Contractor, and DPT shall cause revised Approved Plans reflecting such
        changes to be prepared by Architect, and Connetics shall be responsible
        for all costs or cost increases, resulting from or attributable to the
        Change Order.

               (b) By Connetics. If Connetics at any time desires any changes,
        alterations or additions to the Approved Plans with respect to any of
        the Project, Connetics shall submit a Change Order to DPT. Upon receipt
        of any such request, DPT shall notify Connetics as soon as is reasonably
        possible as to:

                      (i) whether the matters proposed in the Change Order are
               approved by DPT (which approval shall not be unreasonably
               withheld, delayed or conditioned,

                      (ii) DPT's estimate of the number of days of delay, if
               any, which shall be caused by such Change Order if implemented
               (including, without limitation, delays due to the need to obtain
               any revised plans or drawings and any governmental approvals),
               and

                      (iii) DPT's estimate of the increase or decrease, if any,
               which shall occur

                                     Page 4
<PAGE>

               for the items or components affected by such Change Order if such
               Change Order is implemented (including, but not limited to, any
               costs of compliance with laws or governmental regulations that
               become applicable because of the requested Change Order).

        If Connetics notifies DPT in writing, within five (5) business days
        after receiving DPT's estimate of the impact of the Change Order, that
        Connetics approves the Change Order (including the estimated delays and
        cost increases or decreases, if any, described in the notice), then
        Connetics shall enter into such Change Order with the General Contractor
        and Connetics shall be responsible for all costs or cost increases,
        resulting from or attributable to the Change Order. If Connetics fails
        to notify DPT in writing that it approves such Change Order within five
        (5) business days after receiving DPT's estimate of the impact of the
        Change Order, then such Change Order shall be deemed to be withdrawn and
        shall be of no further effect.

        SECTION 3.4. COMPLETION.

               (a) When DPT believes the Project is complete subject only to
        completion of Punch List Work, it shall notify Connetics of the
        Substantial Completion of the Project.

               (b) At any time within thirty (30) days after notice of
        Substantial Completion, Connetics shall be entitled to submit one or
        more lists to the General Contractor specifying Punch List Work to be
        performed on the Project, which shall be completed at the expense of
        either Connetics or the General Contractor, as specified pursuant to the
        Construction Contract.

        SECTION 3.5. TIMING OF COMPLETION. Connetics shall use its commercially
reasonable efforts to complete such construction promptly, diligently and within
the applicable time periods set forth in the Estimated Construction Schedule
attached as EXHIBIT B and incorporated into this Agreement by this reference, as
such schedule may be modified from time to time, subject to the effects of any
delays beyond the parties' reasonable control.

        SECTION 3.6. CONSENT OF OWNER. DPT shall be solely responsible for
securing the consent and approval of the owner of the Premises for the
construction of the Project.

        SECTION 3.7. DESIGNATED REPRESENTATIVES.

               (a) Connetics' Representative. Connetics designates [*]
        (collectively and individually, Connetics' Authorized Representative) as
        the persons authorized to approve all plans, drawings, change orders and
        approvals pursuant to this Agreement.

               (b) DPT's Representative. DPT designates [*] (collectively and
        individually, DPT's Authorized Representative) as the persons authorized
        to approve all plans, drawings, change orders and approvals pursuant to
        this Agreement.

* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to the
  omitted portions.

                                     Page 5
<PAGE>

                                    ARTICLE 4
                    COVENANTS, WARRANTIES AND REPRESENTATIONS

        SECTION 4.1. DPT'S WARRANTIES AND REPRESENTATIONS. DPT hereby makes the
following representations and warranties to Connetics as of the date of this
Agreement:

               (a) DPT has full power and lawful authority to enter into and
        carry out the terms and provisions of this Agreement and to execute and
        deliver all documents which are contemplated by this Agreement, and all
        actions of DPT necessary to confer such power and authority upon the
        persons executing this Agreement (and all documents which are
        contemplated by this Agreement) on behalf of DPT have been taken;

               (b) The Project shall not violate any applicable law, building
        code, regulation or ordinance in effect at the time such improvements
        are placed in service.

               (c) To DPT's knowledge, DPT has received, no written notice from
        any governmental authorities that eminent domain proceedings for the
        condemnation of the Premises are pending;

               (d) To DPT's knowledge, DPT has received no written notice of any
        threatened or pending litigation, arbitration, unsatisfied orders or
        judgments, governmental investigations or proceedings against DPT or
        affecting the Premises which would materially affect the Premises or
        DPT's capacity to perform under its Agreement;

               (e) To DPT's knowledge, DPT has received no written notice from
        any governmental authority that the Premises or any of the improvements
        located on the Premises are presently in violation of any applicable
        building codes, zoning or land use laws, or other law, order, ordinance,
        rule or regulation affecting the Premises.

               (f) To DPT's knowledge (i) there has not been any release of any
        Hazardous Substance on or beneath the Premises in violation of any
        applicable law, and (ii) DPT has received no written notice of any
        violation of claimed violation of any law, rule, or regulation relating
        to Hazardous Substances;

               (g) To DPT's knowledge, there are no conditions which would
        materially and adversely affect the Premises or any part thereof or the
        intended use and development thereof.

               (h) DPT has received all necessary consents and approvals from
        the owner of the Premises.

        SECTION 4.2. DPT'S COVENANTS. DPT hereby covenants and agrees as
follows:

        (a) During the time the Project is under construction, DPT shall comply
with its obligations under any applicable contracts or permits, and shall
maintain reasonable

                                     Page 6
<PAGE>

        levels and coverages of insurance in accordance with customary business
        practice and SECTION 6.1 of this Agreement. DPT shall not create or
        acquiesce in the creation of liens or exceptions to title or voluntarily
        take any action to render any of the representations or warranties of
        DPT set forth in SECTION 4.1 materially incorrect.

               (b) DPT shall promptly notify Connetics of any event or
        circumstance of which DPT becomes aware subsequent to the date of this
        Agreement which (a) materially and adversely affects the Premises or the
        use or operation of the Premises, or (b) makes any representation or
        warranty of DPT to Connetics under this Agreement untrue or misleading.

        SECTION 4.3. CONNETICS' WARRANTIES AND REPRESENTATIONS. Connetics hereby
represents and warrants to DPT that (a) Connetics has full power and lawful
authority to enter into and carry out the terms and conditions of this Agreement
and to execute and deliver all documents which are contemplated by this
Agreement, (b) Connetics shall comply with its obligations under any applicable
contracts or permits and (c) all actions necessary to confer such power and
authority upon the persons executing this Agreement and all documents which are
contemplated by this Agreement to be executed on behalf of Connetics or its
assignee have been taken.

        SECTION 4.4. DPT INDEMNIFICATION. DPT shall indemnify and defend
Connetics against and hold Connetics harmless from any and all third party
claims, liabilities, losses, damages, costs and expenses, including, without
limitation, all reasonable attorneys' fees, asserted against or suffered by
Connetics resulting from (a) any breach by DPT of this Agreement, and (b) any
liability or obligation arising in connection with DPT's use of the Premises on
or before the date of this Agreement.

        SECTION 4.5. CONNETICS INDEMNIFICATION. Connetics shall indemnify and
defend DPT against and hold DPT harmless from any and all third party claims,
liabilities, losses, damages, costs and expenses, including, without limitation,
all reasonable attorneys' fees, asserted against or suffered by DPT resulting
from (a) any breach by Connetics of this Agreement, or (b) any liability or
obligation arising in connection with Connetics' ownership or use of the Assets.

                                    ARTICLE 5
                               ONGOING OBLIGATIONS

        SECTION 5.1. OWNERSHIP. It is understood and agreed that Connetics shall
be the owner of the Equipment and the aerosol filling facility built on the
Premises (collectively, the "Assets"), to the extent the Assets can be removed
upon expiration of the Lease Agreement. Connetics acknowledges that its
ownership may be subject to certain rights of the landlord of the Premises to
fixtures installed on the Premises. Connetics shall be responsible for removal
and disposal of the Assets upon expiration of the Manufacturing and Supply
Agreement and restoration of the Leased Premises to the same condition as in
existence prior to the effective date hereof. DPT shall cooperate with Connetics
in filing any UCC-1 or equivalent financing statement to secure Connetics'
investment in the Assets. Connetics shall have the full right to depreciate the
Assets, and to control the use and disposition of the Assets.

                                     Page 7
<PAGE>

        SECTION 5.2. USE OF THE PREMISES.

               (a) It is the intent of both Parties to use the Assets as a
        source of income for both Parties. The Parties therefore contemplate
        that DPT will not use the facilities or the Equipment comprising the
        Project in connection with other customers' products without
        compensating Connetics for such use. Unless otherwise stated below, the
        specific terms of any such sharing of income shall be mutually agreed by
        the Parties, in the course of good faith negotiations conducted at a
        later time.

               (b) DPT shall be entitled to use the Assets for its affiliates or
        third parties for cosmetic and over-the-counter drug products without
        obtaining the prior written consent of Connetics, provided that the use
        does not interfere with Connetics's capacity requirements and DPT pays
        to Connetics [*]

               (c) DPT shall be required to secure Connetics' prior written
        consent to use the Assets for any prescription dermatological product,
        which consent shall not be unreasonably withheld.

               (d) In all events, in case of a shortage of capacity, Connetics
        shall have first priority regarding use of the facilities and Equipment
        comprising the Project, and will not be deemed to be acting in bad faith
        if it withholds consent in order to secure such priority rights.

               (e) If in the future the need for increased capacity arises,
        Connetics shall be responsible for all capital expenditures needed to
        increase the capacity unless the Parties otherwise agree.

        SECTION 5.3. RENTAL FEE. During the term of this Agreement or for as
long as Connetics owns the Assets, whichever is longer, Connetics shall pay DPT
rental for Connetics' pro rata portion of the Premises, to offset expenses of
operating the facility. Rent is currently $4.63 per square foot per year, and
is subject to adjustment in the event DPT's rent is increased in the future. The
total square footage allocable to Connetics for purposes of calculating the
rental fee under this SECTION 5.3 is set forth in EXHIBIT C.

        SECTION 5.4. PERSONAL PROPERTY TAX. Connetics shall be responsible for
and shall pay prior to delinquency all taxes and assessments levied against or
by reason of

               (a) any and all alterations, additions and items installed or
        placed on or in the Premises and taxed as personal property rather than
        as Premises, and/or

               (b) all personal property, trade fixtures and other property
        owned by Connetics and utilized on or about the Premises, including the
        Equipment. Connetics shall submit an annual rendition for personal
        property taxes associated with the Assets in accordance with local laws
        and regulations.

* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to the
  omitted portions.

                                     Page 8
<PAGE>

        SECTION 5.5. REAL PROPERTY TAX. DPT shall be responsible for the payment
of all Premises taxes levied and assessed for any calendar or tax year upon the
Premises, provided that any increase due to the improvements added pursuant to
this Agreement shall be the responsibility of Connetics.

        SECTION 5.6. PAYMENT OF OPERATING EXPENSES.

               (a) DPT shall be responsible for the payment of the following
        described Operating Expenses in connection with the Facility.

               (b) Definition of Operating Expenses. Subject to the exclusions
        and provisions contained in this Section, the term "Operating Expenses"
        shall mean the following costs and expenses incurred by DPT for
        operation and maintenance of the Premises:

                      (i) insurance premiums for insurance carried by DPT
               pursuant to SECTION 6.1 (which may include, at DPT's option,
               flood, earthquake or environmental remediation insurance),
               insurance deductibles;

                      (ii) the routine operation, repair and maintenance (but
               excluding major breakdowns and material capital expenditures
               relating to the Assets) of the Premises, including the aerosol
               filling facility, in a cGMP compliant condition including but not
               limited to lighting standards, landscaping, sewers, water, gas
               and electrical distribution systems and facilities, drainage
               facilities, and all signs, both illuminated and non-illuminated,
               that are on the Premises;

                      (iii) commissioning and general facility and equipment
               qualification costs;

                      (iv) except as set forth in Sections 5.4 and 5.5 above,
               real and personal property taxes and assessments levied or
               assessed against the Premises or any part of the Premises,
               including (but not limited to) any possessory interest, use,
               business, license or other taxes or fees, any taxes imposed
               directly on rents or services, any assessments or charges for
               police or fire protection, housing, transit, open space, street
               or sidewalk construction or maintenance or other similar services
               from time to time by any governmental or quasi-governmental
               entity, and any other new taxes on DPT in addition to taxes now
               in effect;

                      (v) supplies, equipment, utilities and tools used in the
               operation and maintenance of the Premises;

                      (vi) property management fees;

                                     Page 9
<PAGE>

        SECTION 5.7. UTILITIES/PERMITS. DPT shall be responsible for the payment
to the supplier of all charges for water, trash collection, hazardous waste
disposal, gas, heat, light, electricity, power, sewer, telephone, alarm system,
janitorial and other services or utilities supplied to or consumed in or with
respect to the Premises, including any taxes on such services and utilities.
Connetics shall be responsible for the payment of any necessary Building Permits
or Fees associated with the Project.

        SECTION 5.8. MAINTENANCE AND REPAIRS.

               (a) Except as set forth in Section 5.6(b)(ii) above, DPT shall,
        at its sole cost and expense, keep and maintain the Premises (and every
        part of the Premises) and the Equipment in good working order.

               (b) DPT shall not use the Premises or the Equipment, or permit
        the Premises or the Equipment to be used, in whole or in part for any
        purpose or use that violates any applicable laws, ordinances,
        regulations or rules of any governmental agency or public authority now
        in force or which may hereafter be in force pertaining to the use of the
        Premises, including, without limitation, regulations applicable because
        of the construction of improvements in or other particular use of the
        Premises.

        SECTION 5.9. FDA CERTIFICATION. It shall be DPT's obligation to ensure
that the Project, when completed, complies with all laws and regulations
promulgated by the FDA relating to the manufacture of pharmaceuticals, including
cGMP regulations.

        SECTION 5.10. TRANSFER OF ASSETS. DPT shall not permit any change of
control or assignment of the Assets without Connetics prior written consent,
such consent not to be unreasonably withheld.

                                    ARTICLE 6
                             INSURANCE AND INDEMNITY

        SECTION 6.1. INSURANCE AND INDEMNITY.

               (a) DPT's Insurance. DPT shall keep and maintain, or cause to be
        kept and maintained a policy or policies of insurance on the Premises
        insuring the same against loss or damage by the following risks: fire
        and extended coverage, vandalism, malicious mischief, and sprinkler
        damage, in amounts not less than ninety percent (90%) of full
        replacement value of the Premises. The term "full replacement value"
        shall mean actual replacement cost, including changes required by new
        building codes or ordinances (exclusive of the cost of excavation,
        foundations and footings). Such insurance shall show, as a loss payee in
        respect of the Premises, DPT, Connetics, and the owner of the Premises.
        DPT shall provide proof of insurance to Connetics annually.

               (b) Connetics' Risk. Connetics at its cost may carry such
        insurance as Connetics desires for Connetics' protection with respect to
        the Equipment and the

                                    Page 10
<PAGE>

        construction of the Project, and with respect to the Assets following
        completion of the Project.

               (c) Other Insurance. During the period of construction of the
        Premises, Builder's All Risk Insurance with Completed Operations
        Coverage, in such amounts and with such deductibles and other terms as
        DPT may reasonably require; and

        SECTION 6.2. ADJUSTMENT IN THE EVENT OF LOSS. Except as otherwise
provided in this Agreement, all insurance proceeds payable with respect to any
damage or destruction to the Premises (but not with respect to the Equipment, it
being understood that insurance proceeds allocable to the Equipment shall be
payable directly to Connetics) shall be payable to DPT. Each Party agrees to
execute and deliver to the other Party such releases, endorsements and other
instruments as the other Party reasonably may require in order to compromise,
adjust or settle any insurance claim which such other Party shall be entitled to
compromise, adjust or settle pursuant to this paragraph and to enable the other
Party or its designee to collect such insurance proceeds as are payable in
respect of such claim.

                                    ARTICLE 7
                                   LIMITATIONS

        SECTION 7.1 NO IMPLIED REPRESENTATIONS; WARRANTIES OR CONDITIONS. EXCEPT
AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER DPT NOR Connetics
MAKES ANY REPRESENTATIONS OR WARRANTIES AND THERE ARE NO CONDITIONS, EXPRESS OR
IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO PRODUCT SUPPLIED UNDER THIS
AGREEMENT, INCLUDING, WITHOUT LIMITATION, ANY REPRESENTATIONS, WARRANTIES OR
CONDITIONS WITH RESPECT TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE
OF SUCH PRODUCT, OR ARISING FROM A COURSE OF DEALING OR USAGE OF TRADE PRACTICE.

        SECTION 7.2 LIMITATION OF LIABILITY. IN NO EVENT SHALL EITHER PARTY HAVE
ANY LIABILITY TO THE OTHER PARTY OR ANY OTHER THIRD PARTY FOR ANY LOST
OPPORTUNITY, COSTS OF PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES, OR FOR ANY
SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES ARISING OUT OF
THIS AGREEMENT, UNDER ANY CAUSE OF ACTION OR THEORY OF LIABILITY (INCLUDING
NEGLIGENCE), AND WHETHER OR NOT SUCH PARTY TO THIS AGREEMENT HAS BEEN ADVISED OF
THE POSSIBILITY OF SUCH DAMAGES. THESE LIMITATIONS SHALL APPLY NOTWITHSTANDING
ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY.

                                    ARTICLE 8
                                  MISCELLANEOUS

        SECTION 8.1. NOTICES. Any notices permitted or required by this
Agreement shall be sent by certified or registered mail with a copy by fax and
shall be effective the earlier of the date

                                    Page 11
<PAGE>

received or three (3) days after deposit in the U.S. mail, if sent and addressed
as follows or to such other address as either Party may designate in writing:

        If to DPT:             DPT Laboratories, Ltd.
                               Attention: President
                               P.O. Box 1659
                               San Antonio, Texas 78296
                               Fax: (210) 227-6132
                               with a copy to the General Counsel's Office

        If to Connetics:       Connetics Corporation
                               Attention: President
                               3290 West Bayshore Road
                               Palo Alto, California 94303

        SECTION 8.2. NO AGENCY. Nothing contained in this Agreement shall make
or constitute either DPT or Connetics as the agent of the other.

        SECTION 8.3. MERGER. All understanding and agreements, oral and written,
previously made between the Parties and relating to the matters covered in this
Agreement are merged in this Agreement. This Agreement, along with its exhibits
and the documents referenced in and contemplated by the exhibits, and the
Manufacturing and Supply Agreement of even date herewith, fully and completely
expresses the agreement between DPT and Connetics with regard to the matters set
forth in this Agreement. No modification of any of the terms of this Agreement,
or any amendments to this Agreement, shall be deemed to be valid unless in
writing and signed by the Party against which enforcement is sought. No course
of dealing or usage of trade shall be used to modify the terms and conditions in
this Agreement. Nothing in this Agreement is intended to alter the status of any
of (a) the Research & Development Services Agreement, or (b) the Confidentiality
and Material Transfer Agreement already in effect between the Parties, or (c)
the Supply and Manufacturing Agreement to be entered into by the Parties in
connection with commercial manufacture of Connetics' products.

        SECTION 8.4.  GOVERNING LAW AND DISPUTE RESOLUTION

        (a)    Governing Law

               The validity, interpretation and effect of this Agreement shall
               be governed by and construed under the laws of the State of
               Texas, U.S.A.

        (b)    Mediation

               The Parties agree to attempt to settle any disputes that arise in
               connection with this Agreement through good faith non-binding
               mediation efforts. The Parties agree that any dispute that arises
               in connection with this Agreement which is not settled through
               good faith mediation efforts and which does not involve a claim
               for equitable relief shall be settled by arbitration according to
               the provisions of SECTION 8.4(c) below.

                                    Page 12
<PAGE>

        (c)           Arbitration

               (i)    Any dispute, claim or controversy arising from or related
                      in any way to this Agreement or the interpretation,
                      application, breach, termination or validity of this
                      Agreement, including any claim of inducement of this
                      Agreement by fraud or otherwise, which is not resolved by
                      good faith mediation efforts, will be submitted for
                      resolution to arbitration pursuant to the commercial
                      arbitration rules then pertaining of the Center for Public
                      Resources ("CPR"), except where those rules conflict with
                      these provisions, in which case these provisions control.
                      Such arbitration shall be held in (A) Santa Clara County,
                      California, if the demand for arbitration is initiated by
                      DPT or (B) Bexar County, Texas, if the demand for
                      arbitration is initiated by Connetics.

               (ii)   A single arbitrator shall be chosen from the CPR Panels of
                      Distinguished Neutrals and shall be a lawyer specializing
                      in business litigation with at least 15 years experience
                      with a law firm of over 25 lawyers or who was a judge of a
                      court of general jurisdiction.

               (iii)  The parties agree to cooperate (A) to obtain selection of
                      the arbitrator within 30 days of initiation of the
                      arbitration, (B) to meet with the arbitrator within 30
                      days of selection and (C) to agree at that meeting or
                      before upon procedures for discovery and as to the conduct
                      of the hearing which will result in the hearing being
                      concluded within no more than 9 months after selection of
                      the arbitrator and in the award being rendered within 60
                      days of the conclusion of the hearings, or of any
                      post-hearing briefing, which briefing will be completed by
                      both sides within 20 days after the conclusion of the
                      hearings. In the event no such agreement is reached, the
                      CPR will select the arbitrator, allowing appropriate
                      strikes for reasons of conflict or other cause and three
                      peremptory challenges for each side. The arbitrator shall
                      set a date for the hearing, commit to the rendering of the
                      award within 60 days of the conclusion of the evidence at
                      the hearing, or of any post-hearing briefing (which
                      briefing will be completed by both sides in no more than
                      20 days after the conclusion of the hearings), and provide
                      for discovery according to these time limits, giving
                      recognition to the understanding of the Parties that they
                      contemplate reasonable discovery, including document
                      demands and depositions, but that such discovery be
                      limited so that the time limits specified in this
                      Agreement may be met without undue difficulty. In no event
                      will the arbitrator allow either side to obtain more than
                      a total of 40 hours of deposition testimony from all
                      witnesses, including both fact and expert witnesses. In
                      the event multiple hearing days are required, they will be
                      scheduled consecutively to the greatest extent possible.

                                    Page 13
<PAGE>

               (iv)   The arbitrator shall render an opinion setting forth
                      findings of fact and conclusions of law with the reasons
                      therefor stated. A transcript of the evidence adduced at
                      the hearing shall be made and shall, upon request, be made
                      available to either Party.

               (v)    To the extent possible, the arbitration hearings and award
                      will be maintained in confidence.

               (vi)   Any court of competent jurisdiction may enter judgment
                      upon any award.

               (vii)  Each party has the right before or during the arbitration
                      to seek and obtain from the appropriate court provisional
                      remedies such as attachment, preliminary injunction,
                      replevin, etc. to avoid irreparable harm, maintain the
                      status quo, or preserve the subject matter of the
                      arbitration.

               (viii) EACH PARTY TO THIS AGREEMENT WAIVES ITS RIGHT TO TRIAL OF
                      ANY ISSUE BY JURY.

               (ix)   The decision of the arbitrator shall be final and binding
                      upon all Parties and their respective successors and
                      assigns.

        (d)    Costs

               The costs of mediation and/or arbitration, including reasonable
               attorneys' fees, shall be borne by the losing Party, as allocated
               by the arbitration award.

        SECTION 8.5. NO WAIVER. No waiver by either Party of any default on its
obligations under this Agreement shall be effective unless in writing, nor shall
any such waiver operate as a waiver of any other default or of the same default
on a future occasion.

        SECTION 8.6. HEADINGS. The headings used in this Agreement are for
convenience only and are not a part of this Agreement.

        SECTION 8.7. DAYS. All references in this Agreement to a number of days
shall be construed to refer to calendar days, unless otherwise specified in this
Agreement.

        SECTION 8.8. COUNTERPARTS. This Agreement may be executed in
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same original.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first written above.

                                    Page 14
<PAGE>

--------------------------------------------------------------------------------
  CONNETICS CORPORATION                       DPT LABORATORIES, LTD.
  A Delaware Corporation

                                              By:  DFB PHARMACEUTICALS, INC.
                                                   Sole General Partner

  By:   /s/
        ----------------------------
  Name:                                       By:   /s/
         ---------------------------               -----------------------------
  Title:                                      Name:
        ----------------------------                 ---------------------------

--------------------------------------------------------------------------------

                                    Page 15
<PAGE>

                                    EXHIBIT A

[*]

* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to the
  omitted portions.

<PAGE>

                                    EXHIBIT B
                           DEFINITION OF IMPROVEMENTS

The Project referred to in the Agreement to which this Exhibit is attached shall
consist of work described in the following plans:

                                      [*]

* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to the
  omitted portions.

<PAGE>

                                    EXHIBIT C
                            EQUIPMENT AND FACILITIES

                                      [*]

                                [TO BE COMPLETED]

* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to the
  omitted portions.<PAGE>

                                                                   EXHIBIT 10.56

                       MANUFACTURING AND SUPPLY AGREEMENT

                             DPT LABORATORIES, LTD.

                                       AND

                              CONNETICS CORPORATION

        This Manufacturing and Supply Agreement (the "Agreement") is made as of
this 12 day of March, 2002 by and between Connetics Corporation, a corporation
organized under the laws of the State of Delaware, with its principal place of
business at 3290 West Bayshore Road, Palo Alto, California 94303 ("Connetics")
and DPT Laboratories, Ltd., a Texas Limited Partnership with a place of business
at 307 East Josephine Street, San Antonio, Texas 78215 ("DPT"). Connetics and
DPT are sometimes referred to in this Agreement individually as a "Party" and
collectively as the "Parties."

                                   BACKGROUND

        A. Connetics owns certain patented technologies for the formulation and
filling of aerosol pharmaceutical, over-the-counter and cosmetic products.

        B. DPT owns and has a broad spectrum of technologies for the
development, formulation, testing, control, manufacture, filling and
distribution of pharmaceutical, over-the-counter and cosmetic products.

        C. DPT and Connetics are parties to a Research & Development Services
Agreement dated July 20, 2001, which relates to the development and supply of
research products, and which anticipates a separate manufacturing agreement for
the manufacture and supply of commercial Products.

        D. DPT and Connetics have agreed to enter into a transaction whereby
Connetics will provide the necessary capital to construct an aerosol
filling/packaging operation on DPT's leased distribution facilities, and DPT
will manufacture and fill Connetics aerosol products. That transaction will be
memorialized in a Contribution Agreement between the Parties.

        NOW, THEREFORE, in consideration of the mutual covenants expressed
below, the Parties agree as follows:
<PAGE>

                                 1 - DEFINITIONS

ACT

        "Act" means the Federal Food, Drug and Cosmetic Act, as amended, and
        regulations promulgated thereunder.

AQL

        "AQL" means Acceptable Quality Limits.

BULK PRODUCT

        "Bulk Product" means a drug product that has been manufactured but not
        filled or packaged into a final dosage presentation.

cGMPS

        "cGMPs" means the current Good Manufacturing Practices of the FDA, as
        set forth in Title 21 of the U.S. Code of Federal Regulations.

CONTRACT MINIMUMS

        "Contract Minimums" means either [*] of Connetics Product and/or
        Connetics licensed product, as further described in SECTION 3.1.

FDA

        "FDA" means the United States Food and Drug Administration, or any
        successor entity thereto.

FORECASTED NEEDS

        "Forecasted Needs" means Connetics' estimate of Products to be ordered
        from DPT for each of the twelve (12) months following the month in which
        such estimate is provided.

INITIAL PROJECT

        "Initial Project" means the construction and qualification of the
        production and laboratory aerosol filling facilities referred to in
        ARTICLE II.

* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to the
  omitted portions.

                                       2
<PAGE>

LABEL, LABELED, OR LABELING

        "Label", "Labeled", or "Labeling" means all labels and other written,
        printed, or graphic matter upon: (i) Product or any container or wrapper
        utilized with Product or (ii) any written material accompanying Product.

MANUFACTURING FEE

        "Manufacturing Fee" means the fee paid by Connetics to DPT for services
        required to manufacture and package Products. The Manufacturing Fee is
        quoted in single final Product unit increments (i.e., by the bottle, can
        or tube). The Manufacturing Fee shall include services for incoming
        inspection of materials (including costs associated with establishing,
        testing and storing Raw Materials or Components), compounding of bulk,
        packaging Product, testing Product for release, making Product ready for
        shipment, and minimum product documentation (one copy of Certificate of
        Analysis, batch records). The Manufacturing Fee does not include,
        without limitation, any research & development support, package
        engineering studies, validation support, FDA audit support, extensive
        reporting requirements, or additional laboratory testing performed by an
        outside testing laboratory or testing beyond that required in the
        Specifications, warehousing or distribution of Product, any materials
        costs or costs associated with establishing or manufacturing new
        materials such as art charges, die costs, plate costs, or packaging
        equipment change parts.

MARKET YEAR

        "Market Year" means a period of twelve (12) consecutive months
        commencing on the first day of the month following the initial invoicing
        of Product commercially manufactured by DPT in accordance with this
        Agreement and beginning on January 1st of each consecutive year
        thereafter.

MATERIALS FEE

        "Materials Fee" is quoted in single final Product unit increments and is
        defined as DPT's Standard Cost plus mark-up of 8% for administration and
        carrying costs. Materials Fee does not include, without limitation,
        costs associated with establishing, testing or manufacturing components
        or new materials such as reference standards, reagents, art charges, die
        costs, mold or tooling costs, plate costs, or packaging equipment change
        parts. These items will be invoiced to Connetics at DPT's cost net
        thirty (30) days and Connetics agrees to reimburse DPT for any such
        authorized expenditures made on Connetics' behalf.

                                       3
<PAGE>

MATERIAL SAFETY DATA SHEET

        "Material Safety Data Sheet" ("MSDS") means written or printed material
        concerning a hazardous chemical which is prepared in accordance with the
        regulations promulgated by the Occupational Safety & Health
        Administration, or any successor entity thereto.

PCR

        "PCR" means Product Change Request.

PACKAGING

        "Packaging" means all primary containers, cartons, shipping cases,
        inserts or any other like material used in packaging, or accompanying,
        Product.

PRODUCT(s)

        "Product(s)" means product(s) listed in SCHEDULE A manufactured,
        packaged, labeled and/or finished by DPT pursuant to this Agreement.

QUALITY AGREEMENT

        "Quality Agreement" means the Quality and Technical Agreement between
        DPT and Connetics dated March, 2002, as it may be amended from time to
        time, a copy of which is attached as SCHEDULE B.

RAW MATERIALS AND/OR COMPONENTS

        "Raw Materials and/or Components" means any and all raw materials and
        components (such as chemicals, containers, closures, packaging,
        labeling, etc.) other than the Bulk Product needed by DPT to manufacture
        and supply Product to Connetics according to the terms and conditions of
        this Agreement.

REGULATORY FILINGS

        "Regulatory Filings" means new drug applications (including abbreviated
        or supplemental new drug applications) and other filings with the FDA or
        equivalent international agencies, requesting approval to market and
        sell Product.

                                       4
<PAGE>

REJECTED PRODUCT

        "Rejected Product" shall have the meaning set forth in SECTION 3.7.

SPECIFICATIONS

        "Specifications" means the (1) raw material specifications (including
        chemical, micro, and packaging specifications); (2) sampling
        requirements (i.e., lab, chemical, and micro); (3) compounding module,
        including compounding process and major equipment; (4) intermediate
        specifications; (5) packaging module (including packaging procedures,
        torque and fill weights); and (6) finished Product specifications
        release criteria including DPT's AQL's. Specifications shall be
        established and/or amended from time to time upon the written agreement
        of both DPT and Connetics via a PCR in accordance with ARTICLE IX below.

STANDARD COST

        "Standard Cost" means the average actual cost to DPT of materials plus
        incoming freight plus yield loss adjustment.

TOTAL PRICE

        "Total Price" is the price per Unit of Product payable by Connetics
        pursuant to SECTION 3.10.

                        II - AEROSOL FILLING FACILITIES

2.1  AEROSOL FILLING FACILITIES

        DPT agrees to design, build, obtain necessary permits and licenses for,
and manage an aerosol filling facility consisting of a production line and a
laboratory line (collectively, the "Initial Project") in San Antonio, Texas. The
Initial Project will support both cGMP research and development work and cGMP
commercial production capable of filling at an approximate rate of [*]. The
design and cost estimates for the facility shall be prepared by DPT and approved
in advance by Connetics. The agreement of the Parties with respect to all
aspects of the construction and use of the aerosol filling facility will be the
subject of a separate agreement between the Parties.

* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to the
  omitted portions.

                                       5
<PAGE>

2.2  LINE USE FEE

        (a) During the term of this Agreement (including any extensions), DPT
shall pay Connetics a line use fee any time DPT uses the R&D line previously
funded by Connetics, or the production or laboratory lines of the aerosol
filling facility, to manufacture any product for its affiliates or a third
party.

        (b) The amount of the line use fee shall be calculated as follows (or in
such different manner as the Parties may agree in the future):

               [*]

The line use fee is due and payable to Connetics sixty (60) days after DPT first
invoices the third party for manufacturing the product.

        (c) The line use fee payable pursuant to this SECTION 2.2 shall be over
and above any royalty required to be paid to manufacture under Connetics'
patents. It is understood that the manufacture of any product that infringes any
Connetics patent will require payment of a patent royalty by DPT or the third
party in an amount to be negotiated at the time.

                      III - PRODUCT MANUFACTURE AND SUPPLY

3.1  MANUFACTURE AND PURCHASE; MINIMUMS

* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to the
  omitted portions.

                                       6
<PAGE>

        (a)    Subject to the terms and conditions of this Agreement, DPT agrees
               that it will manufacture for and provide to Connetics the
               Products. Connetics shall pay DPT for Products as set forth in
               SECTIONS 3.8 and 3.9. DPT shall manufacture Products in
               accordance with the Specifications and the Quality Agreement, and
               in sufficient quantity to meet Connetics Forecasted Needs for the
               length of this Agreement. The development of new product
               candidates will continue to be governed by the Research &
               Development Services Agreement.

        (b)    Connetics shall be required to purchase a minimum number of units
               from DPT per year ("Contract Minimums"), according to the
               schedule set forth below. If Connetics does not purchase the
               minimum requirement during a given 12-month period, then at the
               end of that 12-month period Connetics shall pay DPT an amount
               equal to [*]

        (c)    The initial Contract Minimum shall be [*] for two years,
               beginning 6 months after the opening of the commercial production
               line (currently estimated to open in [*]. The Contract Minimum
               will increase to [*] beginning 30 months after the commercial
               production line is opened. The Contract Minimum can be satisfied
               by the production of any combination of Products, or third party
               products that are licensed by Connetics (e.g., minoxidil foam).

3.2     SUPPLY OF MATERIALS

        (a)    It shall be the obligation of DPT to obtain, supply and store all
               Raw Materials and Components for the manufacture of the Products.
               DPT shall use commercially reasonable efforts to obtain the best
               price for all Raw Materials and Components.

        (b)    If for any reason Connetics undertakes to supply any Raw
               Materials or Components for manufacture of Products, the
               following requirements shall apply:

               i.     Connetics shall notify DPT, in writing, specifying which
                      materials or components it will supply.

               ii.    Connetics shall provide DPT with said materials at
                      Connetics' expense along with Certificates of Analysis and
                      MSDS sheets relating to same, at a minimum of thirty (30)
                      days prior to DPT's scheduled production of Product
                      requiring said materials and in sufficient amounts for
                      DPT's manufacture of Product but not to exceed quantities

* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to the
  omitted portions.

                                       7
<PAGE>

                      necessary to support three (3) months of the most recently
                      supplied Forecasted Needs or the minimum order quantity
                      whichever is greater. Connetics-supplied material in
                      excess of these amounts shall be either subject to storage
                      fees or returned to Connetics.

               iii.   All Connetics supplied material shall be shipped to DPT
                      freight prepaid. If Connetics ships or causes to ship such
                      material freight collect, DPT shall invoice Connetics for
                      the cost of the freight plus a reasonable administrative
                      fee which invoice shall be paid promptly upon receipt.

               iv.    DPT is hereby authorized by Connetics to return any
                      portion of Connetics supplied material for which no future
                      production is planned.

               v.     Connetics shall be responsible for the quality of all
                      Connetics-supplied materials.

               vi.    Connetics shall be responsible for the payment of all
                      personal property and other taxes incident to the storage
                      of Connetics-owned material at DPT.

               vii.   For each lot of materials supplied by Connetics, DPT shall
                      perform the quality control and inspection tests as agreed
                      to in the Specifications and pursuant to DPT's Standard
                      Operating Procedures. DPT shall have the right to reject
                      any pre-approved material which does not meet the
                      Specifications in accordance with SECTION 2.3 below.

               viii.  DPT warrants that it will maintain, for the benefit of
                      Connetics, complete and accurate records of the inventory
                      of all such Connetics-supplied materials.

               ix.    If requested by Connetics, DPT will provide to Connetics a
                      monthly report of ending monthly inventory balance of each
                      Connetics supplied/owned materials stored at DPT. This
                      reporting will be supplied exclusively on DPT forms.

        (c)    DPT shall be responsible for supply, at the expense of Connetics
               pursuant to subsection (d) below, of all other commodities
               necessary for the manufacture of Products.

        (d)    Connetics shall provide DPT with Specifications (including art
               proofs) for packaging and labeling, and DPT shall purchase, at
               the expense of Connetics, packaging and labeling in accordance
               with the Specifications.

                                       8
<PAGE>

        (e)    DPT shall invoice Connetics for all Raw Materials and Components
               supplied by DPT in connection with the Product into which the Raw
               Materials and Components were converted, as part of the Materials
               Fee, in accordance with the provisions of SECTION 3.8.

3.3     MATERIALS TESTING

        All materials and packaging supplies shall, when received by DPT, be
        submitted to analysis and evaluation in accordance with DPT's SOP's and
        the Quality Agreement. The cost of all such analyses and evaluations
        shall be borne by DPT, except as otherwise provided in SECTION 3.2 of
        this Agreement.

3.4     MATERIAL SAFETY DATA SHEETS

        With respect to any Raw Materials and Components furnished by Connetics
        pursuant to SECTION 3.2(b), before DPT receives and tests such
        Connetics-supplied material, and as a condition precedent of any testing
        or formulation work by DPT pursuant to this Agreement, Connetics shall
        provide MSDS sheets to DPT. Any components or Products requiring
        disposal shall be presumed hazardous unless otherwise provided in the
        MSDS information provided.

3.5     DPT'S DUTIES

        (a)    DPT shall maintain sufficient quantities of the Bulk Product and
               the Raw Materials and Components to manufacture the Product in
               accordance with the terms and conditions of this Agreement. DPT
               shall coordinate with Connetics before qualifying any alternate
               sources of Bulk Product or Raw Materials and Components. Any Bulk
               Product and Raw Materials and Components shall meet the
               applicable Specifications.

        (b)    DPT shall assume all responsibility and risk for the safekeeping,
               storage and handling of all Bulk Product and Raw Materials and
               Components.

        (c)    DPT, agrees, at its sole cost and expense, that it shall maintain
               any and all licenses, permits and consents (including without
               limitation, facility licenses and permits required by applicable
               laws) necessary and/or required for DPT to manufacture the
               Product and otherwise perform its obligations under this
               Agreement.

        (d)    Each shipment of Product under this Agreement shall have been
               manufactured in accordance with cGMPs and the Specifications in

                                       9
<PAGE>

        a duly licensed facility and in accordance with the provisions of the
        Quality Agreement. DPT shall number each Product shipment with a vendor
        lot number that is traceable to Raw Materials and/or Components used to
        manufacture such Product.

3.6     FAILURE TO SUPPLY

        DPT shall immediately notify Connetics if DPT is unable to fill any
        purchase order placed by Connetics pursuant to SECTION 3.8 for any
        reason, including without limitation force majeure) and advise Connetics
        of the revised delivery date. Connetics shall then have the option of
        terminating any such Purchase Order without obligation of payment or of
        accepting the revised delivery date.

3.7     FORECASTS

        No later than six (6) months prior to the initial Market Year of a new
        Product added to this Agreement, Connetics agrees to notify DPT of its
        delivery requirements, including firm orders for same, for the initial
        three (3) months and shall provide its Forecasted Needs for the first
        Market Year in order to ensure timely delivery of Product for initial
        sale and marketing.

3.8     PURCHASE ORDERS

        (a)    Connetics agrees to purchase from DPT all Products manufactured
               for Connetics by DPT in accordance with cGMP and Connetics'
               purchase orders or Forecasted Needs to the extent such Products
               meet the Specifications or exceptions approved by Connetics.

        (b)    Products shall be ordered by Connetics by the issuance of
               separate, pre-numbered purchase orders in increments of full
               batch quantities.

        (c)    No later than six (6) months prior to the initiation of the first
               Market Year and thereafter at the end of each month, Connetics
               shall provide DPT with specific data as to its Forecasted Needs.
               It is understood and agreed that with respect to all Forecasted
               Needs issued to DPT by Connetics pursuant to the terms of this
               Agreement, the forecast for the first three (3) months thereof
               shall constitute a firm order for Products, regardless of whether
               or not Connetics issues actual purchase orders. DPT may produce
               Product up to thirty (30) days prior to the requested delivery
               date in order to accommodate fluctuations in production demands.
               The second three (3) months of the period addressed in all
               Forecasted Needs shall be utilized by DPT for purposes of
               material acquisition

                                       10
<PAGE>
               on behalf of Connetics and DPT production planning. DPT shall
               attempt to minimize the material inventory purchased on behalf of
               Connetics. Certain materials, however, may have long lead times
               and/or require a minimum order quantity. Therefore, DPT may order
               the [*] necessary to support up to six (6) months of Connetics'
               Forecasted Needs, or the applicable minimum order quantity,
               whichever is greater. Should Connetics subsequently reduce its
               Forecasted Needs, Connetics will be financially responsible for
               any material purchased by DPT on Connetics' behalf. DPT may
               require a deposit for such materials and such materials may also
               be subject to storage and inventory carrying cost fees.

        (d)    Connetics shall provide at least one hundred twenty (120) days
               lead time prior to the requested delivery dates if the
               requirements for any new forecast exceed the most recent
               Forecasted Needs by more than one hundred twenty-five percent
               (125%).

3.9     REJECTED PRODUCTS

        (a)    Connetics may reject any Product which fails to meet the
               Specifications ("Rejected Product"). Connetics shall, within
               twenty (20) days after its receipt of any shipment of Product and
               related Certificate of Analysis of Product batch (as described in
               SECTION 5.1 of this Agreement), notify DPT in writing of any
               claim relating to rejected Product batch and, failing such
               notification, shall be deemed to have accepted such Product
               batch. Such notice to DPT shall specify why the Product batch
               failed to perform to Specifications. Connetics shall grant to DPT
               the right to inspect or test said Product batch. All Products
               shall be submitted to inspection and evaluation in accordance
               with DPT's SOP's to determine whether or not said Products meet
               the Specifications.

        (b)    As to any Rejected Product pursuant to SECTION 3.7(a) above
               (including phases of or complete batches of bulk product), DPT
               shall replace such Rejected Product (in an agreed upon batch
               order quantity, but in no event less than full batch increments)
               promptly after all materials are available to DPT for the
               manufacture. If requested, DPT shall make arrangements with
               Connetics for the return or disposal of Rejected Product.

        (c)    If a Rejected Product clearly results from DPT's equipment
               failure, damage from DPT's facilities, and/or DPT's misweighing
               of chemicals, DPT shall bear one hundred percent of all costs
               directly related to and invoiced by DPT for Rejected Product,
               including costs of destruction, but excluding the cost of any
               materials supplied by Connetics. Except as provided in the
               preceding

* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to the
  omitted portions.

                                       11
<PAGE>

               sentence, for the initial three (3) batches and all validation
               batches of a Product produced by DPT, or in the event a Rejected
               Product is due to Connetics supplied information, formulations or
               materials, Connetics shall bear one hundred percent (100%) of all
               costs directly related to and invoiced by DPT for Rejected
               Product including cost of destruction of the Rejected Product,
               which shall be conducted by Connetics in accordance with all
               applicable laws and regulations.

        (d)    If a validated Product does not meet final Specifications and
               results in a Rejected Product, but such failure is not clearly
               due to either Connetics supplied information or DPT's equipment
               failure, failure to follow written Specifications, damage from
               DPT's facilities and/or DPT's misweighing of chemicals, Connetics
               shall bear all Materials Fees with DPT bearing all Manufacturing
               Fees related to Rejected Product, and with destruction to be paid
               by the Connetics.

        (e)    Destruction of Rejected Product shall be in accordance with all
               applicable laws and regulations and the party conducting the
               destruction shall indemnify the other party hereto for any
               liability, costs or expenses, including attorney's fees and court
               costs, relating to a failure to dispose of such Product in
               accordance with such laws and regulations. The party conducting
               the destruction shall also provide to the other party hereto all
               manifests and other applicable evidence of proper destruction as
               may be requested by applicable law.

        (f)    In the event of a conflict between the test results of DPT and
               the test results of Connetics with respect to any shipment of
               Product batch, a sample of such Product batch shall be submitted
               by DPT to an independent laboratory acceptable to both parties
               for testing against the Specifications utilizing the methods set
               out in the Specifications. The fees and expenses of such
               laboratory testing shall be borne entirely by the party against
               whom such laboratory's findings are made. If results from the
               independent laboratory are inconclusive, final resolution will be
               settled in accordance with SECTION 14.6(b) below.

3.10    PRODUCT PRICE

        (a)    Price for Connetics' Products. Connetics shall pay DPT for
               Products a price per Unit of Product equal to the Manufacturing
               Fee plus the Materials Fee. Any services related to services not
               included in the Manufacturing Fee, such as research & development
               support, package engineering studies, validation support, FDA
               audit support, extensive reporting requirements, or additional
               laboratory testing performed by an outside testing

                                       12
<PAGE>

               laboratory or testing beyond that required in the Specifications,
               shall be billed by the hour at DPT's then-prevailing R&D hourly
               rate in accordance with the Research & Development Agreement
               between the Parties dated July 20, 2001.

        (b)    Manufacturing Fees. The initial Manufacturing Fees to be paid by
               Connetics to DPT are listed in SCHEDULE C. The Parties agree that
               the Manufacturing Fees set out in SCHEDULE C shall be
               re-negotiated, in good faith, at the beginning of each calendar
               year. If the parties are unable to agree on a re-negotiated price
               at least thirty (30) days prior to the start of a new twelve (12)
               month period, then this Agreement, effective the first day of
               January of the new twelve (12) month period, shall continue in
               force with prices being adjusted to reflect the change in the
               Producer Price Index for the Pharmaceutical Sector ("PPI") during
               the preceding twelve (12) month period until such time as to when
               price negotiation can be completed. Prices for new Products or
               new Product sizes, not initially included in SCHEDULE C, shall be
               negotiated and DPT and Connetics shall arrive at a mutual
               agreement with respect to prices at the time said new Products or
               new Product sizes are added to SCHEDULE A. If a negotiated price
               cannot be agreed upon, final pricing for any of the above will be
               settled in accordance with SECTION 13.6(b).

        (c)    Materials Fees. The Materials Fee to be paid by Connetics to DPT
               shall be listed in SCHEDULE C within ninety (90) days of
               commencement of manufacturing of the initial commercial products
               of the applicable Product. The Materials Fee will be adjusted
               once annually at the beginning of each calendar year and SCHEDULE
               C shall be amended accordingly based on changes in DPT's standard
               costs for materials. In the event, however, the cost of a
               material increases or decreases during any Market Year greater
               than ten percent (10%), DPT may promptly upon the effective date
               of such increase or decrease adjust its invoice price for said
               material to Connetics to compensate for the increase or decrease.

3.11    PAYMENT

        (a)    Invoices. DPT shall submit to Connetics an invoice five (5) days
               after DPT's internal release of Product by DPT's quality
               department, or shipment of Product from DPT, whichever occurs
               first. Total invoice shall be equal to the quantity of Product
               released times the Total Price per unit, effective on the date of
               Product release. Connetics shall make payment of each invoice
               within thirty (30) days after receipt by Connetics. If within
               thirty (30) days after the delivery of Product and the
               accompanying Certificate of Analysis to Connetics, Connetics
               demonstrates non-

                                       13
<PAGE>

               conformance under SECTION 3.9 and DPT agrees with such finding,
               Connetics shall not be obligated to pay for such non-conforming
               shipment.

3.12    LATE PAYMENT

        (a)    A late fee of one percent (1%) of total invoice can be added each
               month for late payments. DPT, at its sole discretion, has the
               right to discontinue Connetics' credit on future orders and to
               put a hold on any production or shipment of Product if Connetics'
               account is not current. Such hold on production or shipment shall
               not constitute a breach of this Agreement by DPT. In the event
               credit is discontinued, a one hundred percent (100%) material
               deposit paid by Connetics to DPT will be required prior to DPT
               ordering materials. In addition, a fifty percent (50%)
               Manufacturing Fee deposit will be required prior to DPT
               manufacturing any Product and the balance of the invoice must be
               paid in full prior to shipment.

        (b)    As collateral security for Connetics' payment obligations
               contained in this Agreement, Connetics grants to DPT a security
               interest in all Raw Materials and Components, including
               inventory, work-in-progress, and finished goods ordered or
               produced in connection with this Agreement. Chapter 9 of the
               Texas Uniform Commercial Code shall govern the rights and
               obligations of the Parties relative to the security interests
               granted herein.

3.13    DISPOSAL COSTS

        DPT reserves the right to invoice Connetics for all disposal costs,
        related to manufacture of the Products, unless the disposal relates to a
        Rejected Product causes by the failure of DPT to follow established
        written procedures.

                         IV - SHIPMENT AND RISK OF LOSS

4.1     SHIPMENT

                                       14
<PAGE>

        Shipment of Product shall be in accordance with Connetics instructions,
        provided that shipment is made in accordance with all relevant statutory
        requirements. Product will be shipped to Connetics or its designee
        immediately upon release, freight collect. If Connetics requests DPT to
        make any miscellaneous small shipments of Product, material, or other
        items on Connetics' behalf, Connetics agrees to reimburse DPT for any
        shipping charges incurred.

4.2     DELIVERY TERMS

        The purchase price of Products in SCHEDULE C shall be F.O.B. DPT's plant
        of manufacture, San Antonio, Texas, freight collect. Connetics will bear
        all risk of loss, delay, or damage in transit, as well as cost of
        freight and insurance. Should the parties enter into a Distribution
        Agreement, transfer of title, as well as all risk of loss, shall occur
        upon release of the Product from quarantine.

4.3     CLAIMS

        The weights, tares and tests affixed by DPT's invoice shall govern
        unless established to be incorrect. Claims relating to quantity, weight
        and loss or damage to any Product sold under this Agreement shall be
        waived by Connetics unless made within thirty (30) days of receipt of
        Product by Connetics.

                            V - TERM AND TERMINATION

5.1     TERM

        This Agreement shall commence on the first day of the month following
        the mutual signing of this document and will continue until the
        expiration of the Tenth (10th) Market Year for each Product added to
        SCHEDULE A, unless sooner terminated pursuant to SECTION 5.2 below. This
        Agreement shall thereafter automatically renew for periods of 36 months,
        unless any Party shall give notice to the others to the contrary at
        least 12 months prior to the expiration of the initial term or any
        renewal term of the Agreement.

5.2     TERMINATION

        This Agreement may be terminated at any time upon the occurrence of
        either of the following events:

                                       15
<PAGE>

        (a)    The failure of either Party to comply with its obligations in
               this Agreement, which failure is not remedied within sixty (60)
               days after written notice thereof.

        (b)    Notice by either Party to the other upon the insolvency or
               bankruptcy of the other Party.

5.3     PAYMENT ON TERMINATION

        In the event of the termination or cancellation of this Agreement for
        any reason, and without prejudice to any other rights and remedies
        available to DPT hereunder, Connetics agrees to reimburse DPT the
        Materials Fee for Raw Materials and Components ordered for the
        manufacture of Products based on Connetics' Forecasted Needs, as well as
        for work-in-process and finished Products.

5.4     SURVIVAL

        Termination of this Agreement under SECTION 5.2 or due to expiration or
        cancellation shall not relieve either party of obligations or liability
        for breaches of this Agreement incurred prior to or in connection with
        termination, expiration or cancellation. Articles VI, VII, IX, X, XI and
        XII of this Agreement shall survive the termination or cancellation of
        this Agreement for any reason.

5.5     EFFECT OF TERMINATION. Upon termination of this Agreement the following
        shall occur:

        (a)    DPT shall have no right to manufacture Product or use any of
               Connetics Confidential Information, and all rights, title or
               interest in, or other incidents of ownership under, Connetics
               Confidential Information, including the right to manufacture
               Product, shall automatically revert to Connetics. In the event
               any such termination relates solely to one or more Products, then
               this Agreement shall only be terminated to the extent it applies
               to such Product(s) and this Agreement shall remain in effect as
               it applies to all other Product(s);

        (b)    except as otherwise provided in this Agreement, expiration or
               termination of this Agreement shall not relieve the Parties of
               any obligation accruing prior to such expiration or termination;

        (c)    within 30 days following the expiration or termination of this
               Agreement, each Party shall return to the other Party, or
               destroy, upon the written request of the other Party, any and all
               Confidential Information of the other Party in its possession and
               upon a Party's

                                       16
<PAGE>

               request, such destruction (or delivery) shall be confirmed in
               writing to such Party by a responsible officer of the other
               Party, except for such Confidential Information which the
               receiving Party is required to keep under Applicable Laws, in
               which event such Confidential Information shall be held subject
               to the terms and conditions of Article XI.

5.5     REMEDIES

        All of the non-breaching Party's remedies shall be cumulative, and the
        exercise of one remedy by the non-defaulting Party shall not be deemed
        to be an election of remedies. These remedies shall include the
        non-breaching Party's right to sue for damages for such breach without
        terminating this Agreement.

            VI- CERTIFICATES OF ANALYSIS AND MANUFACTURING COMPLIANCE

6.1     CERTIFICATES OF ANALYSIS

        DPT shall test each lot of Product purchased pursuant to this Agreement
        before delivery to Connetics, in accordance with the Quality Agreement.

6.2     STABILITY TESTING

        DPT shall perform its standard stability test program as defined in
        DPT's SOP's and the Quality Agreement.

6.3     VALIDATION WORK OR ADDITIONAL TESTING

        It is understood by the Parties that the responsibility for any
        validation work shall be the sole responsibility of Connetics. The
        parties agree that for any validation work or additional testing in
        connection with the Product, DPT and Connetics shall enter into a
        specific written Project Protocol establishing methodology and pricing
        for such services. It is understood between the Parties that if DPT is
        required by regulatory authority to perform validation studies or
        additional testing in order to legitimately continue to engage in the
        manufacture of the Product for Connetics and DPT and Connetics cannot
        reach an agreement on a written Project Protocol, then DPT shall be
        under no obligation to continue the manufacture of the Product affected
        by said regulation.

6.4     FDA INSPECTION

                                       17
<PAGE>

        DPT shall advise Connetics if an authorized agent of the FDA or other
        governmental agency visits DPT's manufacturing facility and requests or
        requires information or changes which directly pertain to the Products.
        FDA audit time specific to Products will be billed to Connetics from DPT
        at the then-prevailing QA hourly rate. DPT agrees to provide Connetics
        with copies of any written observations made in connection with such
        inspections, and any written responses to those observations.

6.5     REGULATORY FILINGS

        Connetics agrees to provide DPT with copies of any sections of any
        Regulatory Filings applicable to the Products manufactured and/or tested
        by DPT, and copies of any changes in or updates of same as they, from
        time to time, hereafter occur.

                                       18
<PAGE>

                                VII - WARRANTIES

7.1     REPRESENTATIONS AND WARRANTIES.

        (a)    Subject to SECTIONS 7.2 and 7.3, DPT warrants that Product
               delivered to Connetics pursuant to this Agreement shall, at the
               time of release:

               (i)    have been manufactured, filled, packaged and stored in all
                      material respects in accordance with all applicable U.S.
                      laws, rules, regulations or requirements;

               (ii)   have been manufactured, filled, packaged and stored in
                      accordance with, and will conform to, the Product
                      Specifications or pursuant to exceptions approved by
                      Connetics at the time of manufacture and shipment;

               (iii)  be free from defects in material, manufacturing and
                      workmanship for the shelf life of the Product as set forth
                      in the Product Specifications; and

               (iv)   not be (as a result of the actions or omissions of DPT)
                      adulterated or misbranded within the meaning of the
                      Federal Food, Drug and Cosmetic Act (the "Act") as
                      amended, or within the meaning of any applicable state or
                      municipal law in which the definitions of adulteration and
                      misbranding are substantially the same as those contained
                      in the Act, as the Act and such laws are constituted and
                      effective at the time of delivery.

        (b)    Licensing. DPT represents and warrants that it has obtained and
               will maintain on a current basis and will comply with all
               licenses, permits and approvals of applicable governmental
               agencies as may be required to manufacture, test and store the
               Product pursuant to this Agreement and perform its other
               obligations under this Agreement. DPT shall be responsible for
               obtaining and maintaining licenses and permits for manufacture,
               testing and storage of the Product and ensuring that its
               facilities used in the manufacture of the Product meet cGMPs in
               all respects.

        (c)    Compliance with Laws. DPT represents and warrants that it shall
               comply in all material respects with all U.S. federal, state, and
               local laws, regulations and other requirements applicable to the
               manufacture, testing and storage of the Product and the
               performance of DPT's obligations under this Agreement. DPT shall

                                       19
<PAGE>

               have sole responsibility for adopting and enforcing safety
               procedures for the handling and manufacture of the Product at its
               facilities and the proper handling and proper disposal of waste
               relating to the Product.

7.2     COMPLIANCE WITH THE ACT

        Connetics shall bear sole responsibility for the validity of all test
        methods and appropriateness of all Specifications. In addition,
        Connetics shall bear sole responsibility for all regulatory approvals,
        filings, and registrations and adequacy of all validation, stability,
        and preservative efficacy studies. Connetics further warrants that it
        shall have obtained any and all necessary approvals from all applicable
        regulatory agencies necessary to manufacture and distribute all Products
        under this Agreement prior to their introduction into interstate
        commerce.

7.3     COMPLIANCE OF PACKAGING AND LABELING WITH LAWS AND REGULATIONS

        Connetics warrants that all Labeling copy and artwork approved,
        designated or supplied by Connetics shall be in compliance with all
        applicable laws and governmental regulations. Compliance with all
        federal, state, and local laws and regulations concerning Packaging and
        Labeling shall be the sole responsibility of Connetics, provided that
        DPT purchases such Packaging and Labeling as provided in SECTION 3.2(c)
        of this Agreement. Connetics hereby represents and warrants to DPT that
        all Connetics designated formulas, components and artwork related to the
        Product do not violate or infringe any patent, copyright or trademark
        laws, and agrees to indemnify DPT, its employees, officers, directors
        and representatives for any claim, loss or damage including reasonable
        attorney's fees paid or incurred by any of them in connection therewith.

7.4     ACCESS TO DPT'S FACILITIES

        Connetics shall have reasonable access to DPT's facilities for the
        purpose of observing manufacturing of Products under this Agreement.
        Connetics shall have access to DPT's facilities at a mutually agreeable
        time for the sole purpose of auditing DPT's compliance with current Good
        Manufacturing Practices and the Act. Such access shall in no way give
        Connetics the right to any of DPT's confidential or proprietary
        information. Further, audits shall normally be limited to every eighteen
        (18) months and three (3) employees of Connetics who are subject to the
        same requirements of confidentiality as Connetics.

                                       20
<PAGE>

7.5     LIMITATIONS; INDEMNIFICATION

        (a)    Limitations on Warranty. The warranty furnished in SECTION 7.1(b)
               shall not apply to defects caused by accident or willful damage,
               abuse, misuse, neglect, improper testing, handling, storage or
               use after delivery by DPT of the Product in question to
               Connetics.

        (b)    No Implied Representations; Warranties or Conditions. EXCEPT AS
               OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER DPT NOR
               Connetics MAKES ANY REPRESENTATIONS OR WARRANTIES AND THERE ARE
               NO CONDITIONS, EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, WITH
               RESPECT TO PRODUCT SUPPLIED UNDER THIS AGREEMENT, INCLUDING,
               WITHOUT LIMITATION, ANY REPRESENTATIONS, WARRANTIES OR CONDITIONS
               WITH RESPECT TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR
               PURPOSE OF SUCH PRODUCT, OR ARISING FROM A COURSE OF DEALING OR
               USAGE OF TRADE PRACTICE.

        (c)    Limitation of Liability. EXCEPT FOR ANY LOSS, LIABILITY, DAMAGE
               OR OBLIGATION ARISING OUT OF OR RELATING TO THE DISCLOSURE OF
               CONFIDENTIAL INFORMATION PURSUANT TO ARTICLE 7 OR AS OTHERWISE
               EXPRESSLY SET FORTH IN THIS AGREEMENT, IN NO EVENT SHALL EITHER
               PARTY HAVE ANY LIABILITY TO THE OTHER PARTY OR ANY OTHER THIRD
               PARTY FOR ANY LOST OPPORTUNITY, COSTS OF PROCUREMENT OF
               SUBSTITUTE GOODS OR SERVICES, OR FOR ANY SPECIAL, INDIRECT,
               INCIDENTAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES ARISING OUT OF
               THIS AGREEMENT, UNDER ANY CAUSE OF ACTION OR THEORY OF LIABILITY
               (INCLUDING NEGLIGENCE), AND WHETHER OR NOT SUCH PARTY TO THIS
               AGREEMENT HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
               THESE LIMITATIONS SHALL APPLY NOTWITHSTANDING ANY FAILURE OF
               ESSENTIAL PURPOSE OF ANY LIMITED REMEDY.

                                       21
<PAGE>

                             VIII - PRODUCT RECALLS

        If at any time or from time to time:

               (a)    the FDA or any other government authority requests,
                      directs, or orders a Party to recall or withdraw the
                      Product;

               (b)    a court of competent jurisdiction issues an order or
                      directive for the Product to be recalled or withdrawn; or

               (c)    a voluntary recall or withdrawal of the Product is
                      contemplated by either Party

        (individually or collectively, a "Recall"), then the Party to whom such
        request is made or the Party contemplating such Recall, as the case may
        be, shall immediately notify the other Party. Neither Party shall carry
        out a voluntary Recall in the Territory without the prior written
        approval of the other Party, which approval shall not be unreasonably
        withheld, conditioned or delayed. The Parties acknowledge and understand
        due to the immediacy of any recall situation, such approval should be
        given in 48 hours.

        In addition, the Parties shall take all appropriate corrective actions
        reasonably requested by the other Party hereto or by any government
        agency. In the event that such recall results from the breach of DPT's
        warranties under this Agreement, DPT shall be responsible for the
        expenses of the Recall, in any case not to exceed one hundred thousand
        dollars ($100,000.00) per Recall incident. In the event the Recall
        results from the breach of Connetics' warranties under this Agreement,
        Connetics shall be responsible for the expenses of the Recall. For the
        purposes of this Agreement, the expenses of the Recall shall be the
        expenses of notification and destruction or return of the recalled
        Product, as well as any reasonable out-of-pocket costs incurred by DPT
        and Connetics in connection with any corrective action taken by DPT and
        Connetics.

                               IX - FORCE MAJEURE

        Failure of either party to perform its obligations under this Agreement
        shall not subject such party to any liability to the other if such
        failure is caused by acts such as, but not limited to, acts of God,
        fires, explosion, flood, drought, war, riot, sabotage, embargo, strikes,
        compliance with any court order or regulation of any government entity
        acting with color of right or by any other cause beyond the reasonable
        control of the parties, whether or not foreseeable.

                                       22
<PAGE>

                       X - CHANGES TO PROCESS OR PRODUCT

10.1    CHANGES BY CONNETICS

        If Connetics at any time requests a change to Product and DPT agrees
        such change is reasonable with regard to Product manufacture; (i) such
        change shall be incorporated within the Master Batch Record and/or
        Specifications via a written PCR reviewed and agreed upon by both DPT
        and Connetics; (ii) The parties shall adjust the price of Product, if
        necessary, and SCHEDULE A shall be amended accordingly; and (iii)
        Connetics shall pay DPT for the costs associated with such change
        including, but not limited to, any additional development or validation
        work required, charged at DPT's then-prevailing R&D rates in accordance
        with Article XII contained in this Agreement.

10.2    CHANGES BY DPT

        DPT agrees that any changes developed by DPT which may be incorporated
        into the Product shall require the written approval of Connetics via a
        PCR prior to implementation of the change. At the time of such
        incorporation, such changes shall become part of the Specifications. No
        such change may be instituted except in compliance with this Agreement
        and the Quality Agreement. It is also agreed that any regulatory filings
        incident to any such change shall be the sole responsibility of
        Connetics. Connetics shall have the option of obtaining, or having DPT
        obtain, any required FDA approval or other regulatory approval prior to
        implementation of such a change.

10.3    CHANGES BY REGULATORY AUTHORITIES

        The parties agree that any changes required by regulatory authority,
        shall be incorporated into the Product as evidenced by the written
        approval of Connetics via a PCR prior to such incorporation. At the time
        of such incorporation, such changes shall become part of the
        Specifications. If DPT is required by regulatory authority to perform
        validation studies for purposes of validating new manufacturing process
        or cleaning procedures or new material and finished Product assay
        procedures with respect to Product in order to continue to engage in the
        manufacture of said Product for Connetics, such studies shall be
        conducted in accordance with SECTION 6.3 in this Agreement. Any costs to
        DPT resulting from the operation of this Section shall be reimbursed by
        Connetics.

                                       23
<PAGE>

10.4    OBSOLETE INVENTORY

        Any Connetics-specific inventory including, but not limited to,
        materials, work-in-process, and Products rendered obsolete as a result
        of formula, artwork or packaging changes requested by Connetics or by
        changes required by regulatory authority shall be reimbursed to DPT by
        Connetics at DPT's Materials Fee. At such time and unless otherwise
        agreed by DPT, DPT will ship the obsolete inventory to Connetics for
        destruction by Connetics. Connetics shall bear one hundred percent
        (100%) of all shipping and destruction costs related to said obsolete
        inventory. The destruction shall be in accordance with all applicable
        laws and regulations and Connetics shall indemnify DPT for any
        liability, costs or expenses, including attorney's fees and court costs,
        relating to Connetics' failure to dispose of such inventory in
        accordance with such laws and regulations. Connetics shall also provide
        DPT with all manifests and other applicable evidence of proper
        destruction as may be requested by DPT or required by applicable law. If
        DPT does not receive disposition instructions from Connetics within
        ninety (90) days from date of obsolescence, obsolete inventory remaining
        at DPT's facilities shall be subject to storage fees.

           XI - CONFIDENTIAL INFORMATION: INTELLECTUAL PROPERTY RIGHTS

11.1    CONFIDENTIAL INFORMATION

        The Confidentiality and Material Transfer Agreement between DPT and
        Connetics dated April 12, 2001 is hereby incorporated in its entirety by
        this reference, and shall remain in effect until the later of (a)
        expiration according to its terms, or (b) five years following the
        expiration or termination of this Agreement. The terms of the
        Confidentiality and Material Transfer Agreement shall be deemed amended
        to the extent necessary to cover Products under this Agreement. For
        convenient reference, a copy of the Confidentiality Agreement is
        attached as SCHEDULE D.

11.2    TRADEMARKS AND TRADE NAMES

        (a)    Each Party hereby acknowledges that it does not have, and shall
               not acquire, any interest in any of the other Party's trademarks
               or trade names unless otherwise expressly agreed.

        (b)    Each Party agrees not to use any trade names or trademarks of the
               other Party, except as specifically authorized by the other Party
               in writing both as to the names or marks which may be used and as
               to the manner and prominence of use.

                                       24
<PAGE>

                              XII - INDEMNIFICATION

12.1    INDEMNIFICATION BY DPT

        Subject to SECTION 7.6 above, DPT will indemnify and hold Connetics
        harmless against any and all liability, damage, loss, cost, or expense
        (including reasonable attorney's fees) resulting from any third party
        claims made or suits brought against Connetics which arise from DPT's
        breach of its warranties set forth in Article VII of this Agreement,
        provided such sum does not exceed available insurance coverage.

12.2    INDEMNIFICATION BY CONNETICS

        Connetics will indemnify and hold DPT harmless against any and all
        liability, damage, loss, cost or expense (including reasonable
        attorney's fees) resulting from any third party claims made or suits
        brought against DPT which are related to the breach of any of Connetics'
        warranties provided for in this Agreement or which arise out of the
        promotion, distribution, use, testing or sales of Products, including,
        without limitation, any claims, express, implied or statutory, made as
        to the efficacy, safety, or use to be made of Products, and claims made
        by reason of any Product Labeling or any Packaging containing Product
        (provided such packaging and Labeling was purchased by DPT as provided
        in SECTION 3.2(c) of this Agreement), unless such liability, damage,
        loss or expense is caused by the breach of DPT's warranties under
        Article VII of this Agreement.

12.3    PATENT AND OTHER INTELLECTUAL PROPERTY RIGHTS

        (a)    Connetics further warrants that use of Products or sales of
               Products will not infringe any patent or other proprietary rights
               and that Connetics will indemnify, defend and hold DPT harmless
               from any damage, judgment, loss, cost or other reasonable expense
               (including reasonable attorney's fees) arising from claims that
               Products or the use of the Product names and any other
               trademarks, trade names, or trade dress used by Connetics in
               connection with Products infringes patent or other proprietary
               rights of a third party.

        (b)    DPT shall indemnify and hold Connetics harmless from all costs,
               damages and expense (including reasonable attorney's fees)
               arising out of any suit or action brought against Connetics based
               upon a claim that any process or technical data furnished or
               utilized by DPT infringes any patent or other proprietary rights.

                                       25
<PAGE>

12.4    CONDITIONS OF INDEMNIFICATION

        If either Party expects to seek indemnification from the other under
        SECTIONS 12.1, 12.2, or 12.3 of this Agreement, it shall promptly give
        notice to the other party of any such claim or suit threatened, made or
        filed against it which forms the basis for such claim of indemnification
        and shall cooperate fully with the other party in the defense of all
        such claims or suits. No settlement or compromise shall be binding on a
        party hereto without its prior written consent.

12.5    EVIDENCE OF LIABILITY INSURANCE

        It is further agreed that each Party shall furnish to the other evidence
        of products and contractual liability insurance coverage affording not
        less than one million dollars ($1,000,000) each occurrence combined
        single limit, bodily injury/property damage and one million dollars
        ($1,000,000) aggregate liability limits. Each insurer shall name the
        other as an additional insured. Such evidence of insurance coverage can
        be in the form of the original policy or Certificate of Insurance which
        shall provide that the insurer has assumed the liability as provided for
        in this Agreement. In addition, such insurers shall warrant that such
        insurance will not be changed or canceled without at least thirty (30)
        days prior written notice to the respective indemnities.

                            XIII - GENERAL PROVISIONS

13.1    NOTICES

        Any notices permitted or required by this Agreement shall be sent by
        certified or registered mail with a copy by fax and shall be effective
        the earlier of the date received or three (3) days after deposit in the
        U.S. mail, if sent and addressed as follows or to such other address as
        may be designated by either party in writing:

        If to DPT:             DPT Laboratories, Ltd.
                               Attention: President
                               P.O. Box 1659
                               San Antonio, Texas 78296
                               Fax: (210) 227-6132
                               with a copy to the General Counsel's Office

        If to Connetics:       Connetics Corporation
                               Attention: President
                               3290 West Bayshore Road
                               Palo Alto, California 94303

                                       26
<PAGE>

13.2    ENTIRE AGREEMENT; AMENDMENT

        The Parties acknowledge that this document sets forth the entire
        agreement and understanding of the parties and supersedes all prior
        written or oral agreements or understandings with respect to the subject
        matter of this Agreement, and shall supersede any conflicting portions
        of DPT's quotation, acknowledgment and invoice forms and Connetics'
        Purchase Order and other written forms. No modification of any of the
        terms of this Agreement, or any amendments thereto, shall be deemed to
        be valid unless in writing and signed by the party against whom
        enforcement is sought. No course of dealing or usage of trade shall be
        used to modify the terms and conditions in this Agreement. Nothing in
        this Agreement is intended to alter the status of the Research &
        Development Services Agreement or the Confidentiality and Material
        Transfer Agreement already in effect between the parties.

13.3    WAIVER

        No waiver by either party of any default shall be effective unless in
        writing, nor shall any such waiver operate as a waiver of any other
        default or of the same default on a future occasion.

13.4    OBLIGATIONS TO THIRD PARTIES

        Each party warrants and represents that proceeding in this Agreement is
        not inconsistent with any contractual obligations, express or implied,
        undertaken with any third party.

13.5    ASSIGNMENT

        This Agreement shall be binding upon and inure to the benefit of the
        successors or permitted assigns of each of the parties and may not be
        assigned or transferred by either party without the prior written
        consent of the other, which consent will not be unreasonably withheld,
        except that such consent shall not be required in connection with a
        merger or acquisition of a substantial portion of the assets of either
        party by a third party and provided that the successor or assignee
        assumes all obligations imposed in this Agreement. Any assignments,
        including but not limited to, sale, transfer, or license of brand or
        Products, shall not release the original party hereto from their duties
        and obligations under this Agreement.

                                       27
<PAGE>

13.6    GOVERNING LAW AND DISPUTE RESOLUTION

        (a)    Governing Law

               The validity, interpretation and effect of this Agreement shall
               be governed by and construed under the laws of the State of
               Texas, U.S.A.

        (b)    Mediation

               The Parties agree to attempt to settle any disputes that arise in
               connection with this Agreement through good faith non-binding
               mediation efforts. The Parties agree that any dispute that arises
               in connection with this Agreement which is not settled through
               good faith mediation efforts and which does not involve a claim
               for equitable relief shall be settled by arbitration according to
               the provisions of SECTION 13.6(c) below.

        (c)    Arbitration

               (i)    Any dispute, claim or controversy arising from or related
                      in any way to this Agreement or the interpretation,
                      application, breach, termination or validity of this
                      Agreement, including any claim of inducement of this
                      Agreement by fraud or otherwise, which is not resolved by
                      good faith mediation efforts, will be submitted for
                      resolution to arbitration pursuant to the commercial
                      arbitration rules then pertaining of the Center for Public
                      Resources ("CPR"), except where those rules conflict with
                      these provisions, in which case these provisions control.
                      Such arbitration shall be held in (A) Santa Clara County,
                      California, if the demand for arbitration is initiated by
                      DPT or (B) Bexar County, Texas, if the demand for
                      arbitration is initiated by Connetics.

               (ii)   A single arbitrator shall be chosen from the CPR Panels of
                      Distinguished Neutrals and shall be a lawyer specializing
                      in business litigation with at least 15 years experience
                      with a law firm of over 25 lawyers or who was a judge of a
                      court of general jurisdiction.

               (iii)  The parties agree to cooperate (A) to obtain selection of
                      the arbitrator within 30 days of initiation of the
                      arbitration, (B) to meet with the arbitrator within 30
                      days of selection and (C) to agree at that meeting or
                      before upon procedures for discovery and as to the conduct
                      of the hearing which will result in the hearing being
                      concluded within no more than 9 months after selection of
                      the arbitrator and in the award being rendered

                                       28
<PAGE>

                      within 60 days of the conclusion of the hearings, or of
                      any post-hearing briefing, which briefing will be
                      completed by both sides within 20 days after the
                      conclusion of the hearings. In the event no such agreement
                      is reached, the CPR will select the arbitrator, allowing
                      appropriate strikes for reasons of conflict or other cause
                      and three peremptory challenges for each side. The
                      arbitrator shall set a date for the hearing, commit to the
                      rendering of the award within 60 days of the conclusion of
                      the evidence at the hearing, or of any post-hearing
                      briefing (which briefing will be completed by both sides
                      in no more than 20 days after the conclusion of the
                      hearings), and provide for discovery according to these
                      time limits, giving recognition to the understanding of
                      the Parties that they contemplate reasonable discovery,
                      including document demands and depositions, but that such
                      discovery be limited so that the time limits specified in
                      this Agreement may be met without undue difficulty. In no
                      event will the arbitrator allow either side to obtain more
                      than a total of 40 hours of deposition testimony from all
                      witnesses, including both fact and expert witnesses. In
                      the event multiple hearing days are required, they will be
                      scheduled consecutively to the greatest extent possible.

               (iv)   The arbitrator shall render an opinion setting forth
                      findings of fact and conclusions of law with the reasons
                      therefor stated. A transcript of the evidence adduced at
                      the hearing shall be made and shall, upon request, be made
                      available to either Party.

               (v)    To the extent possible, the arbitration hearings and award
                      will be maintained in confidence.

               (vi)   Any court of competent jurisdiction may enter judgment
                      upon any award.

               (vii)  Each party has the right before or during the arbitration
                      to seek and obtain from the appropriate court provisional
                      remedies such as attachment, preliminary injunction,
                      replevin, etc. to avoid irreparable harm, maintain the
                      status quo, or preserve the subject matter of the
                      arbitration.

               (viii) EACH PARTY TO THIS AGREEMENT WAIVES ITS RIGHT TO TRIAL OF
                      ANY ISSUE BY JURY.

               (ix)   The decision of the arbitrator shall be final and binding
                      upon all Parties and their respective successors and
                      assigns.

                                       29
<PAGE>

        (d)    Costs

               The costs of mediation and/or arbitration, including reasonable
               attorneys' fees, shall be borne by the losing Party, as allocated
               by the arbitration award.

13.7    SEVERABILITY

        In the event that any term or provision of this Agreement shall violate
        any applicable statute, ordinance, or rule of law in any jurisdiction in
        which it is used, or otherwise be unenforceable, such provision shall be
        ineffective to the extent of such violation without invalidating any
        other provision of this Agreement.

13.8    HEADINGS, INTERPRETATION

        The headings used in this Agreement are for convenience only and are not
        a part of this Agreement.

13.9    NO HIRING

        During the term of this Agreement, neither Party shall take any
        affirmative action to hire away any employees of the other Party.

13.10  INDEPENDENT CONTRACTOR

        In performing its services under this Agreement, DPT shall act as an
        independent contractor.

13.11   COUNTERPARTS

        This Agreement may be executed in counterparts, each of which shall be
        deemed an original, but all of which together shall constitute one and
        the same original.

                                       30
<PAGE>

        IN WITNESS WHEREOF, the Parties have each caused this Agreement to be
executed by their duly authorized officers as of the date first above written.

CONNETICS                                      DPT LABORATORIES, LTD.

                                               By:  DFB PHARMACEUTICALS, INC.
                                                    Sole General Partner

By: /s/ THOMAS WIGGINS                         By:  /s/
   --------------------------------               ------------------------------

Its: President/CFO                             Its: President
    -------------------------------                -----------------------------

                               INDEX TO SCHEDULES

SCHEDULE A      PRODUCTS
SCHEDULE B      QUALITY AGREEMENT
SCHEDULE C      MANUFACTURING FEES
SCHEDULE D      CONFIDENTIALITY AND MATERIAL TRANSFER AGREEMENT BETWEEN
                DPT AND CONNETICS DATED APRIL 12, 2001

                                     31
<PAGE>

                                   SCHEDULE A
                                    PRODUCTS

                                      [*]

* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to the
  omitted portions.

                                       32
<PAGE>

                                   SCHEDULE B
                                QUALITY AGREEMENT

                                      [*]

* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to the
  omitted portions.

                                       33
<PAGE>

                                   SCHEDULE C
                               MANUFACTURING FEES

                                      [*]

* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to the
  omitted portions.

                                       34
<PAGE>

                                   SCHEDULE D
                 CONFIDENTIALITY AND MATERIAL TRANSFER AGREEMENT
                 BETWEEN DPT AND CONNETICS DATED APRIL 12, 2001

                                      [*]

* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to the
  omitted portions.

                                       35

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00041-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00041-of-00352.parquet"}]]